Kevin is Frontier Medicines’ Chief Scientific Officer bringing deep expertise in drug discovery and clinical development linked with a passion for bringing novel medicines to patients. Prior to joining Frontier Medicines, Kevin was Sr. Vice President of Cancer Biology at eFFECTOR Therapeutics, where he pioneered the discovery and development of a new class of oncology drugs known as selective translation regulators advancing multiple novel targets into clinical development. Prior to eFFECTOR, Kevin was Vice President of Oncology Research at AstraZeneca Pharmaceuticals, where he built and led the oncology discovery organization in Waltham, MA. As a member of the global oncology leadership team, he developed the science strategy for oncology and progressed over a dozen programs into preclinical and clinical development with multiple programs achieving clinical proof of concept and one resulting in a marketed drug. During his tenure with AstraZeneca he was accountable for building a new drug discovery organization in the US, as well as spearheading the creation of novel partnerships with academia and biotech organizations. Before AstraZeneca, Kevin served as a member of the oncology drug discovery leadership team at Bristol Myers Squibb where he led the cell cycle and apoptosis research areas and delivered multiple discovery research projects from inception through early clinical development.

Kevin completed his postdoctoral fellowship at Bristol Myers Squibb. Kevin holds a Ph.D. in Molecular Biophysics and Biochemistry from Yale University, where he studied protein-RNA interactions and translational regulation and a B.S. in Biochemistry from Stony Brook University.